Actelion issues White Paper on Corporate Governance
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion issues White Paper on Corporate Governance
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 08 March 2011 - Actelion Ltd (SIX: ATLN) today
announced a White Paper giving detailed information on the company's Board of
Directors and its approach towards corporate governance.
The White Paper provides details regarding the structure of the Board, the
experience and expertise of individual board members and outlines the processes
in place to ensure adherence to the highest standards of Corporate Governance.
Rob Cawthorn, Chairman of the Board commented: "We see Corporate Governance as
the underpinning foundation for maximizing value creation for our shareholders
through adoption of and compliance with applicable laws and best practices as a
public company. Our Board of Directors is composed of an outstanding group of
people, who bring a wide range of professional expertise from many facets of
corporate life. This expertise, in combination with the Board's structure,
independence, and high level of engagement, provides a great deal of oversight
of the company and its management".
Actelion's board is independent, diverse and experienced. It is composed of nine
directors from six different nationalities, eight of whom are independent. The
directors bring expertise and experience from years of service as CEOs, CFOs,
and COOs of some of the world's most important biotech and pharmaceutical
companies as well as other global corporations and professional bodies.
The board adheres to the highest standards of corporate governance, and provides
rigorous oversight of the company and its management team, via regular meetings,
both as a full board and in various sub-committees. The board regularly reviews
and benchmarks business, operational, and financial performance and assesses the
M&A environment and evaluates the financial plan and related valuation analyses.
Rob Cawthorn concluded: "Since the company's foundation in 1997, Actelion has
delivered sustained value creation through above average growth of revenues and
EBIT which has been reflected in a share price that has more than quadrupled
since the initial public offering in 2000. We believe that the company's
corporate governance has been an important component of enabling this
outstanding performance. We see it as our on- going task to ensure that we have
the right oversight, structure and processes in place to make continued growth
possible also in the future."
The complete White Paper is available on www.actelion.com "Our company" >
"Corporate responsibility" > "Corporate governance"
###
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(®), an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,400 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI(®)).
Actelion's Annual General Meeting of Shareholders approving the Business Report
of the year ending 31 December 2010 will be held on 5 May 2011. In order to
attend and vote at the Annual General Meeting of Shareholders, shareholders must
be registered in the Company's shareholders register by 28 April 2011 at the
latest.
For further information please contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
ISIN: CH0010532478;
Press Release PDF:
http://hugin.info/131801/R/1495457/431209.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1495457]
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2011 - 17:35 Uhr
Sprache: Deutsch
News-ID 52253
Anzahl Zeichen: 5725
contact information:
Town:
Allschwil
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 254 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion issues White Paper on Corporate Governance"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
